We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Andrew
Cope
andrew.cope@kcl.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
ArthrosisInflammatory polyarthropathiesSystemic connective tissue disordersPapulosquamous disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Upon infection, the human body reacts by activating the immune system. Cells of the immune system will activate and mount a response against the pathogen until it has been cleared from the body. Once this has been achieved, the response will shut down and return to a basal situation, ready for the next challenge. However, in some individuals, the immune response is not shut down appropriately and this might lead to a situation where the cells are activated in a chronic manner and may attack their own tissues (this is called an autoimmune reaction). The destruction of the body tissues may lead to the development of an autoimmune disease such as Rheumatoid Arthritis (RA). Despite advances in the knowledge on how the immune response is activated and regulated, the exact mechanism by which this is happening is not fully understood, neither are the differences between healthy and diseased individuals. Our group has described several novel abnormalities in the activation and regulation of the immune cells in autoimmune disease. This study is aimed at dissecting the mechanisms that drive those abnormalities. We will obtain samples from blood and sometimes from inflamed sites such as the synovial fluid from patients with chronic inflammatory diseases such as RA. We will isolate the immune cells and perform extensive laboratory analyses to compare the behavior of cells from healthy and diseased individuals. The results that we will obtain will improve the current understanding of alterations in immune responses in disease and could lead to a better therapy.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
- Individuals who are positive for Human Immunodeficiency virus (HIV) or active for Hepatitis B or C virus infection. - Significant comorbidities such as symptomatic heart disease, malignancies, malnutrition or severe systemic infection, as judged by the supervising physician or research nurse. - Female individuals that are pregnant, breastfeeding or express their wish to conceive. - Patients that are already taking part in trials of investigational medicine products or devices, or other interventions which may have an impact on the patients’ treatment or disease activity. - Patients suffering anemia, defined by haemoglobin levels below 10g/dl. - For healthy volunteers, conditions that might compromise the activation status of their immune system, such as infections. Individuals that are pregnant or breastfeeding and individuals that have given a blood sample of 100ml or more 4 weeks before the sample is taken.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Andrew
Cope
andrew.cope@kcl.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by King's College London and funded by European Commission .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 37860
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
